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ABSTRACT
Objective: The aim of this study was to explore inflammatory response and identify early poten-
tial biomarkers in mid-trimester amniotic fluid associated with subsequent spontaneous preterm
delivery (PTD).
Methods: A cohort study was performed at Sahlgrenska University Hospital/€Ostra, Gothenburg,
Sweden, between 2008 and 2010. Amniotic fluid was collected from consecutive women under-
going mid-trimester transabdominal genetic amniocentesis at 14–19 gestational weeks. Clinical
data and delivery outcome variables were obtained from medical records. The analysis included
19 women with spontaneous PTD and 118 women who delivered at term. A panel of 26 candi-
date proteins was analyzed using Luminex xMAP technology. Candidate protein concentrations
were analyzed with ANCOVA and adjusted for plate effects.
Results: The median gestational age at delivery was 35þ 3weeks in women with spontaneous
PTD and 40þ 0weeks in women who delivered at term. Nominally significantly lower amniotic
fluid levels of adiponectin (PTD: median 130,695pg/mL (IQR 71,852–199,414) vs term: median
185,329pg/mL (IQR (135,815–290,532)), granulocyte-macrophage colony stimulating factor (PTD:
median 137pg/mL (IQR 74–156) vs term: median 176pg/mL (IQR 111–262)), and macrophage
migration inhibitory factor (PTD: median 3025pg/mL (IQR 1885–3891) vs term: median 3400pg/
mL (IQR 2181–5231)) were observed in the spontaneous PTD group, compared with the term
delivery group, after adjusting for plate effects. No significant differences remained after
Bonferroni correction for multiple comparisons.
Conclusions: Our results are important in the process of determining the etiology behind spon-
taneous PTD but due to the non-significance after Bonferroni correction, the results should be
interpreted with caution. Further analyses of larger sample size will be required to determine
whether these results are cogent and to examine whether microbial invasion of the amniotic
cavity or intra-amniotic inflammation occurs in asymptomatic women in the mid-trimester with
subsequent spontaneous PTD.
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Preterm delivery (PTD), defined as delivery before 37
completed weeks of gestation, is a global concern in cur-
rent obstetric and neonatal care [1,2]. It is related to
short- and long-term morbidity in neonates [3] and a
leading cause of neonatal death worldwide [4]. PTD is
mainly categorized in two different phenotypes accord-
ing to the clinical presentation: medically indicated
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(iatrogenic) and spontaneous PTD. The latter occurs in
women with preterm labor (PTL) and preterm prelabor
rupture of membranes (PPROM) [5].
The etiology behind spontaneous PTD is complex.
Previous studies have shown that infection and inflam-
mation are among the main origins [5–13]. Microbes
are believed to ascend from the lower genital tract,
cross the cervical barrier and invade the decidua, cho-
rioamniotic membranes, and presumably sterile amni-
otic cavity [6]. In some cases, this results in an
inflammatory process leading to increased cytokine
release, with subsequent synthesis and release of pro-
inflammatory cytokines, prostaglandins, and proteases
[14]. This triggers myometrial contractions, rupture of
the membranes and cervical maturation, leading to
spontaneous PTD [6,14–16]. Recent research has, how-
ever, suggested that such infections or inflammations
could also arise in utero [17–19] and that some
women have a preexisting subclinical intra-amniotic
inflammation (IAI) very early in gestation. The IAI
might cause part of the increase (0.5%) in miscarriages
associated with mid-trimester amniocentesis [20–23].
Amniotic fluid has a very complex and dynamic
composition that changes as pregnancy progresses [24].
Mid-trimester amniocentesis is a common procedure to
diagnose fetal chromosomal abnormalities and it also
enables investigating other adverse pregnancy outcomes
by examining the protein composition of mid-trimester
amniotic fluid [23]. This can provide insights into basic
biological mechanisms, detect different pathological con-
ditions by reflecting the function of the maternal and
fetal immune systems in the maternal–fetal interface [25]
and provide a unique opportunity to examine the intra-
amniotic environment in asymptomatic women.
Identification of early predictors for adverse pregnancy
outcomes and early detection of women at high risk of
spontaneous PTD are of major physiological and clinical
interest, as the consequences are detrimental to the neo-
nate. However, no single biomarker that possesses sensi-
tivity and predictive ability for the early detection of
spontaneous PTD has yet been identified [26]. Most
likely, coordinated networks of biomarkers, rather than a
single factor, affect the risk of spontaneous PTD [27].
The purpose of this study was to evaluate the asso-
ciation between 26 selected mid-trimester amniotic
fluid candidate cytokines and neuropeptides and the
subsequent development of spontaneous PTD.
Materials and methods
Study design
This is a cohort study of women, aged over 18 years
and with a viable singleton pregnancy, who underwent
mid-trimester transabdominal genetic amniocentesis at
14–19 weeks of gestation at Sahlgrenska University
Hospital/€Ostra, Gothenburg, Sweden, between
September 2008 and July 2010. Women were consecu-
tively enrolled and amniocentesis indications complied
with local guidelines: advanced maternal age (35
years), anxiety, high risk at first-trimester combined
screening or a family history of chromosomal abnor-
malities or genetic diseases. The following women
were not eligible: aged under 18 years, multiple preg-
nancies, positive for HIV or hepatitis B, and known or
suspected fetal malformations. Exclusion criteria were
language difficulties, declined participation, and insuffi-
cient volume of amniotic fluid retrieved at
amniocentesis.
Regional medical records were scrutinized at inclu-
sion and after delivery for clinical data and delivery
outcome variables. Women lost to follow-up, women
who had a legal abortion, and women with severe
chronic diseases (severe cases of, for instance, rheum-
atic disease, hypothyroidism, diabetes mellitus,
asthma, or neurological disorders) were also excluded.
Women with a subsequent spontaneous PTD were
compared with those who delivered at term. For the
sake of homogeneity, the term delivery group was lim-
ited to women delivering between 38þ 0 and 41þ 6
gestational weeks. In order to obtain a representative
estimation of the term delivery group, women were
randomly selected to constitute the reference group.
The group size was determined based on avail-
able samples.
Sample collection and processing
The mid-trimester genetic transabdominal amniocen-
tesis was performed by an experienced operator using
a 22-gauge needle under ultrasound guidance. An
additional 3ml of amniotic fluid was collected for the
study and immediately stored at 4–8 C. Within a few
hours of sampling, the amniotic fluid was centrifuged
for 20min at 4 C and 12,000 g. The supernatant was
separated from the pellet and divided into aliquots
that were frozen and stored at –80 C, awaiting various
batch analyses. All samples were handled according to
a standardized protocol at the same laboratory.
Development of the assay panel
A panel of 26 selected mid-trimester amniotic fluid
candidate cytokines and neuropeptides was developed
based on previous studies in which these proteins
have been associated with spontaneous PTD pathways
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in symptomatic women in the late second or third tri-
mester [28–30]. The panel consisted of the following
selected candidate proteins with the short-form abbre-
viations assigned by the UniProt Consortium within
parentheses; interleukin-1 beta (IL-1b), interleukin-6
(IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), inter-
leukin-12A (IL12A), interleukin-17 [IL17 (IL17A)], inter-
leukin-18 (IL18), interleukin-6 receptor subunit soluble
a (sIL-6RA), adiponectin, brain-derived neurotropic fac-
tor (BDNF), C-reactive protein (CRP), interferon gamma
(IFN-c), granulocyte-macrophage colony stimulating
factor (GM-CSF), insulin-like growth factor binding
protein 1 (IGFBP-1), insulin-like growth factor binding
protein 3 (IGFBP-3), leptin, C-C motif chemokine 2
[monocyte chemotactic protein 1 (MCP-1)], macro-
phage migration inhibitory factor (MIF), C-C motif
chemokine 3 [macrophage inflammatory protein 1-a
(MIP-1-a,)], matrix metalloproteinase-9 (MMP9), neuro-
trophin-3 (NT-3), C-C motif chemokine 5 [T-cell-specific
protein RANTES or T cell-specific protein P228
(RANTES or TCP228)], tumor necrosis factor a (TNF-a),
tumor necrosis factor b (TNF-b), tumor necrosis factor
receptor 1 (TNF-RI), and triggering receptor expressed
on myeloid cells 1 (TREM-1).
Amniotic fluid analysis
The Luminex analysis was planned in advance and
performed at a specific time point. An aliquot of
200 mL of amniotic fluid supernatant from each subject
was sent to the Department of Clinical Biochemistry
and Immunology (Statens Serum Institut, Copenhagen,
Denmark), where the concentrations of the selected
candidate proteins were analyzed using an in-house
multiple sandwich immunoassay based on flowmetric
Luminex xMAP technology, as described previously
[31,32]. The samples were distributed in chronological
order over four plates and analyzed undiluted in
duplicates by investigators blinded to clinical back-
ground and outcome information.
Ethical approval
The study was approved by the Central Ethics Review
Board at the University of Gothenburg, Sweden (Dnr €O
639-03 with several subsequent amendments). Written
informed consent was obtained from all participants.
Statistical analyses
Continuous variables were compared using a nonpara-
metric Mann–Whitney U Test and presented as median
and interquartile range (IQR: 25th; 75th percentiles).
Categorical variables were compared using Fisher’s
exact test and presented as number (%). The concen-
trations of the candidate proteins were logarithmically
transformed and differences between the groups were
analyzed with ANCOVA, adjusting for plate effects as a
potential confounder. Bonferroni correction for mul-
tiple comparisons was subsequently performed.
Differences were considered statistically significant at
p< .05 using a two-sided alternative hypothesis. With
the current sample, we had 80% power to detect
effect sizes (Cohen’s d) of 0.7 at the nominal signifi-
cance level 0.05. The statistical analyses were per-
formed in SPSS 20.0 for Windows XP OS (SPSS Inc,
Chicago, IL) and R version 3.3.1. The control group
was selected by simple random sampling.
Results
Characteristics of the entire study group
Of the 1030 women undergoing mid-trimester genetic
amniocentesis during the study period, 185 women
were not eligible, 387 women were excluded (the
majority of whom declined participation) and 458
were included in the study (54.2%). PTD occurred in
6.3% (29/458), of whom 4.1% (19/458) and 2.2% (10/
458) had a spontaneous and iatrogenic PTD,
respectively.
Of the 429 women with a term delivery, the follow-
ing were excluded: deliveries prior to gestational week
38þ 0 (n¼ 19), deliveries after gestational week 41þ 6
(n¼ 26) and women with severe chronic disease
(n¼ 3). From the remaining group of 381 women, 120
were randomly selected. After analysis and quality
control by perusing medical records, two women were
excluded due to chronic disease, leaving 118 women
in the final reference group (Figure 1).
Maternal and neonatal characteristics of the spon-
taneous PTD and term delivery groups are presented
in Table 1, with gestational age at delivery as the vari-
able defining the groups. A significant difference in
maternal age at sampling (PTD: median 38 years vs
term: median 36 years; p¼ .03) was observed between
the groups. No other significant differences were
found except the obvious difference in birth weight
(PTD: median 2483 grams vs term: median 3555
grams; p< .0001). There were no differences between
the groups regarding gestational age at sampling
(PTD: median 15þ 5weeks (IQR 15þ 2–16þ 1) vs
term: median 15þ 5weeks (IQR 15þ 2–16þ 1);
p¼ .97) nor sample processing or storage
times (p .375).
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Candidate protein levels
The working ranges were set as all concentrations
measurable with a CV% below 20 [31,32] (Table 2).
Concentrations below the working range were set
to half of the lowest concentration in the working
range: Adiponectin, 488.5 pg/mL; BDNF, 10.0 pg/mL;
CRP, 200.0 pg/mL; GM-CSF, 4.0 pg/mL; IGFBP-1,
97.5 pg/mL; IGFBP-3, 97.5 pg/mL; IL-1b, 5.0 pg/mL; IL-6,
Figure 1. Flow chart showing selection of study participants.
Table 1. Maternal and neonatal characteristics in the spontaneous preterm delivery and term delivery groups.
Variable Spontaneous preterm delivery (n¼ 19) Term delivery (n¼ 118) p
Gestational age at delivery (weeksþ days) 35þ 5 (32þ 4–36þ 5) 40þ 0 (39þ 1–40þ 6)
Maternal age at sampling (years) 38 (36–41) 36 (34–39) .03
Nulliparous 6 (31.6%) 32 (27.1%) .78
Maternal BMI at first prenatal visit 24.6 (23.4–26.5) 24.0 (21.9–26.4) .42
Smoking at first prenatal visit 2 (10.5%) 4 (3.4%) .20
Previous preterm delivery 3 (15.8%) 6 (5.1%) .11
Gestational age at sampling (weeksþ days) 15þ 5 (15þ 2–16þ 1) 15þ 5 (15þ 2–16þ 1) .97
Mode of delivery
Vaginal delivery 17 (89.5%) 87 (73.7%) .16
Caesarean section 2 (10.5%) 25 (21.2%) .37
Vacuum extraction 0 (0%) 6 (5.1%) .60
Birth weight (grams) 2483 (2305–2800) 3555 (3240–3843) <.0001
Gender .46
Male 8 (42.1%) 63 (53.4%)
Female 11 (57.9%) 55 (46.6%)
Apgar score <7 at 5min 1 (5.3%) 1 (0.9%) .26
Continuous variables were compared using a nonparametric Mann–Whitney U Test and presented as the median (IQR). Categorical variables were com-
pared using Fisher’s Exact Test and presented as the number (%).
Bold text indicates statistical significance at p<.05 using a two-sided alternative hypothesis.
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19.5 pg/mL; sIL-6RA, 19.5 pg/mL; IL-8, 2.5 pg/mL; IL-10,
10.0 pg/mL; IL12A, 4.0 pg/mL; IL-17, 4.0 pg/mL; IL-18,
10.0 pg/mL; Leptin, 97.5 pg/mL; IFN-c, 4.0 pg/mL; MCP-
1, 2.5 pg/mL; MIF, 49.0 pg/mL; MIP-1-a, 39.0 pg/mL;
MMP-9, 244.0 pg/mL; NT-3, 39.0 pg/mL; RANTES,
2.5 pg/mL; TNF-a, 4.0 pg/mL; TNF-b, 4.0 pg/mL; TNF-RI,
156.5 pg/mL, and TREM-1, 97.5 pg/mL. Concentrations
exceeding the working range were set to the highest
concentration in the working range. In accordance
with the approach reported in previous papers by our
group [33,34], proteins with detectable amniotic fluid
levels in less than 50% of the samples were excluded
from further analyses. This was the case for one pro-
tein, IFN-c, detected in 0.7% of the samples.
Concentrations of the analyzed candidate proteins for
the respective groups are presented in Table 3.
Nominally significantly lower amniotic fluid levels of
adiponectin (PTD: median 130,695 pg/mL (IQR
71,852–199,414) vs term: median 185,329 pg/mL (IQR
135,815–290,532); p¼ .033), GM-CSF (PTD: median
137 pg/mL (IQR 74–156) vs term: median 176 pg/mL
(IQR 111–262); p¼ .049), and MIF (PTD: median
3025 pg/mL (IQR 1885–3891) vs term: median 3400 pg/
mL (IQR 2181–5231); p¼ .042) were found in women
with spontaneous PTD, compared with women
with term delivery, after adjusting for plate effects.
Figure 2 illustrates the correlation between the log
concentrations of the proteins. There was a strong cor-
relation between the three statistically significant pro-
teins. No significance remained after the Bonferroni
correction for multiple comparisons.
The significant difference in maternal age at sam-
pling observed between the groups was analyzed in
relation to the protein levels. The age difference
between the groups was only significant for IGFBP-1
(p¼ .04). Therefore, maternal age was not considered
to be related to the overall protein levels (p¼ .10–.93).
Further, in a multivariable model, we found a correl-
ation between the fetus gender and Leptin, but the
inclusion of the gender in that analysis did not affect
the non-significant relation to spontaneous PTD.
Discussion
This study aimed at evaluating the associations
between the concentrations of 26 selected candidate
proteins in mid-trimester amniotic fluid and the subse-
quent development of spontaneous PTD. The key find-
ings were as follows: (i) amniotic fluid levels of
adiponectin, GM-CSF, and MIF were nominally signifi-
cantly lower in the group of women with subsequent
spontaneous PTD; (ii) a statistically strong correlation
was identified among these three proteins; and iii) no
statistically significant difference remained between
the spontaneous PTD group, compared with the term
delivery group after Bonferroni correction for multiple
comparisons.
Pregnancy and parturition are physiological proc-
esses where inflammatory processes play a central role
[35]. Changes in the immune system must occur to
prevent immune-mediated rejection of the semi-allo-
genic fetus while it must also be maintained, to pre-
vent external pathogens that can affect the mother or
fetus. A strong expression of anti-inflammatory media-
tors and reduced expression of many, but not all,
cytokines linked to host defense and inflammatory
immune capacity are found already in the second tri-
mester of healthy pregnancy [36], leading to an
inflammatory response deployed by the fetus [35]. The
anti-inflammatory phenotype intensifies with increas-
ing gestational age and is self-resolving by one year
post-partum in the absence of repeat pregnancy [36].
Several studies have analyzed the concentrations of
one or a few proteins from mid-trimester amniotic
fluid and their relation to, or possible prediction of,
Table 2. Number of samples of each of the selected candi-
date proteins in the mid-trimester amniotic fluid that were
below the lowest, respectively, exceeded the highest concen-











Adiponectin 977–500,000 0 10
BDNF 20–10,000 0 0
CRP 400–200,000 0 0
GM-CSF 8–4000 0 0
IGFBP-1 195–100,000 0 0
IGFBP-3 195–100,000 0 0
IL-1b 10–5000 1 0
IL-6 39–20,000 0 0
sIL-6RA 39–20,000 0 0
IL-8 5–2500 8 1
IL-10 20–10,000 0 0
IL12A 8–4000 0 0
IL-17 8–4000 1 0
IL-18 20–10,000 56 0
Leptin 195–100,000 0 2
IFN-c 8–4000 147 0
MCP-1 5–2500 0 0
MIF 98–50,000 0 0
MIP-1-a 78–40,000 0 0
MMP-9 488–250,000 0 0
NT-3 78–40,000 0 0
RANTES 5–2500 6 0
TNF-a 8–4000 15 0
TNF-b 8–4000 0 0
TNF-RI 313–160,000 0 0
TREM-1 195–100,000 0 0
The working range represents the lowest and highest concentrations of
the working range. All concentrations are reported in pg/mL.
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subsequent spontaneous PTD [21,23,37–53]. A few
studies have examined a multiplex assay panel of 5–8
candidate proteins from mid-trimester amniotic fluid
in relation to spontaneous PTD [25,54,55]. More com-
prehensive multiplex assay panels from mid-trimester
amniotic fluid have been reported on patients with
cerclage [56], in women expecting twins [57] and in
women with symptoms of threatening PTD in the
second and third trimester [28–30]. A few systematic
reviews and meta-analyses of mid-trimester amniotic
fluid protein levels in relation to spontaneous PTD
have been performed [26,58,59]. The results of previ-
ous studies are conflicting, most likely due to dissimi-
larities in study design and diversities in study
populations [26].
Some of the previous studies have reported higher
levels of inflammatory biomarkers in mid-trimester
amniotic fluid in women with a subsequent spontan-
eous PTD [21,23,37,40–43,47–50,53,54,58], whereas
other studies did not find any significant differences
[25,26,38,39,44–46,51,52,55,59]. Our study design, def-
inition of groups and gestational age at sampling
were most similar to the research by Bamberg et al.
[38] and Puchner et al. [51], who found lower, but
not significantly lower, levels of selected inflamma-
tory mediators in women with spontaneous PTD,
compared with women delivering at term. However,
due to general inconsistency in study design and
diversities in study populations, the results from pre-
vious studies are probably incomparable and further
studies with larger cohorts are needed to elucidate
whether candidate proteins from the mid-trimester
amniotic fluid can predict subsequent spontan-
eous PTD.
Table 3. Amniotic fluid levels of selected candidate proteins in relation to spon-
taneous preterm and term delivery.
Variable Spontaneous preterm delivery (n¼ 19) Term delivery (n¼ 118) p
Adiponectin 130,695 (71,852–199,414) 185,329 (13,5815–290,532) .033
BDNF 822 (555–1241) 995 (677–1328) .087
CRP 16,316 (14,504–16,786) 15,573 (12,811–17,368) .413
GM-CSF 137 (74–156) 176 (111–262) .049
IGFBP-1 14,346 (10,027–16,871) 12,697 (10,860–16,423) .910
IGFBP-3 55,761 (39,577–63,997) 59,417 (42,128–71,168) .320
IL-1b 38 (22–47) 44 (31–64) .118
IL-6 675 (400–1769) 1048 (511–1700) .573
sIL-6RA 1976 (1421–2665) 1753 (1431–2271) .137
IL-8 57 (19–110) 54 (19–125) .669
IL-10 246 (123–350) 276 (185–392) .339
IL12A 43 (24–65) 64 (35–102) .079
IL-17 33 (22–62) 57 (33–88) .157
IL-18 10 (10–25) 24 (10–33) .231
Leptin 8789 (4819–10,468) 7526 (4788–10,434) .757
MCP-1 267 (231–334) 251 (192–344) .399
MIF 3025 (1885–3891) 3400 (2181–5231) .042
MIP-1-a 613 (489–961) 776 (575–1157) .292
MMP-9 6666 (5326–8359) 7358 (6266–9315) .328
NT-3 3257 (2230–4176) 3578 (2370–4885) .183
RANTES 12 (10–15) 14 (11–18) .213
TNF-a 50 (20–96) 85 (40–136) .055
TNF-b 187 (96–253) 252 (153–433) .148
TNF-RI 8179 (6165–8916) 7279 (5963–9137) .724
TREM-1 3206 (2296–6304) 5718 (3630–9307) .060
All concentrations are reported in pg/mL, based on crude data and presented as median and
interquartile range (IQR).ANCOVA adjusting for plate effects.
Bold text indicates statistical significance at p<.05 using a two-sided alternative hypothesis.
Figure 2. Heat map demonstrating the correlation (r) between
the log concentrations of the examined candidate proteins.
Candidate proteins in bold and italics indicate nominal
significance.
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In this study, we found nominally significantly lower
amniotic fluid levels of adiponectin, GM-CSF, and MIF
in the group of women with subsequent spontaneous
PTD, compared with the group of women with a term
delivery. However, the significance did not remain
after Bonferroni correction for multiple comparisons.
Adiponectin is an adipokine with a well-established
role in glucose metabolism and regulation of vascula-
ture. It also has a potent anti-inflammatory effect with
important regulatory effects on both the innate and
adaptive immune response [60]. Adiponectin appears to
be a physiological component of human amniotic fluid
[60–62] and an association between higher levels of adi-
ponectin, PTL, and IAI has previously been reported [60].
Little is, however, known about the concentration, origin
or role of amniotic fluid adiponectin. Baviera et al. [61]
suggested that adiponectin found in amniotic fluid
might be of fetal origin.
Amniotic fluid contains large amounts of GM-CSF,
which probably has various functions [63]. GM-CSF is a
cytokine that promotes white cell maturation and it
participates in the metabolism of pulmonary surfactant
[64]. In early pregnancy, it has also been postulated to
be involved in normal placental function by regulating
the invasion and differentiation of placental tropho-
blast [63]. Little is known about the production of GM-
CSF during pregnancy or in the neonatal period but
Bry et al. [64] suggested that it is developmentally
regulated and that production increases in inflamma-
tory conditions during pregnancy.
MIF has been suggested to be produced by embry-
onic tissues and to have an important function in
embryonic development [65]. MIF has also emerged as
an important cytokine for preventing endotoxic shock
and death associated with bacterial infection. It has
also been studied in relation to IAI and PTD, and PTL
with intact membranes, suggesting that elevated
amniotic fluid concentrations of MIF were associated
with IAI, histologic chorioamnionitis, and shorter
latency from sampling to delivery [66].
Correlations between inflammatory biomarkers
have previously been studied in women with PTL [67]
and women with spontaneous PTD [27], comparing
IAI, sterile IAI, and microbial-associated IAI [67].
Correlations have also been compared in African-
American and Caucasian women with and without
microbial invasion of the intra-amniotic cavity (MIAC)
[27]. However, to the best of our knowledge, this is
the first study specifically focusing on mid-trimester
amniotic fluid and the correlations between the log
concentrations of the examined candidate proteins in
relation to spontaneous PTD.
The strengths of this study are that a broad panel
of selected candidate proteins, previously associated
with spontaneous PTD pathways [28–30], was ana-
lyzed, enabling us to examine how these proteins cor-
relate with each other. None of the examined proteins
were very strong in itself, suggesting that a network
of proteins, rather than a single protein, would affect
the risk of spontaneous PTD. All the amniotic fluid
samples were handled according to a standardized
laboratory protocol and analyzed in one batch at the
same facility. The very low rate of lost-to-follow-ups
and the very thorough correction for plate effects
should also be considered as strengths.
The weaknesses of the study were the low sample
size, which limited the detection of subtle differences
between biomarker concentrations, and the lack of rep-
lication. One limitation might be that the respective PTL
and PPROM phenotypes may differ somewhat, but the
low sample size did not allow this differentiation in the
spontaneous PTD group. Another potential weakness is
that most women were of advanced maternal age or
had a high risk of chromosomal abnormalities, as they
were undergoing amniocentesis for genetic analysis.
Hence, the findings do not reflect the general popula-
tion. Finally, sample size calculation was not performed,
instead, power analysis was used to calculate the small-
est effect size possible to detect given a set sample size.
We do not consider the effect size to be unrealistically
large. With our sample size, we can conclude that there
are no major differences between the groups. Similar
studies have not previously been performed so this
study forms a basis for future larger studies.
The median gestational age at delivery among
women with a spontaneous PTD was 35þ 3weeks in
this cohort. Late spontaneous PTD does not usually
have an infectious or acute inflammatory etiology. It
could thus be discussed whether these results are pri-
marily relevant in the case of late spontaneous PTD,
and whether or not these cases of spontaneous PTD
were based on an infection or inflammation.
The dynamic environment in utero changes as preg-
nancy progresses. Because of the increase in the mis-
carriage rate (0.5%) after mid-trimester
amniocentesis [68], early amniotic fluid samples for
research can only be collected according to clear clin-
ical indications. The timing of cytokine release, the
local environment in which they act, the presence of
competing or synergistic elements, cytokine receptor
density, and tissue responsiveness to each cytokine
could potentially differ during pregnancy, raising the
question of whether this gestational age is the optimal
timing for detection of early IAI. As spontaneous PTD
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can be considered a syndrome caused by heteroge-
neous pathways, the respective optimal gestational
ages might either overlap or digress.
Conclusions
The etiology behind spontaneous PTD is complex and
understanding of the sequence and timing of events
preceding this condition is still incomplete [69]. There
is, thus, an urgent need to study asymptomatic
women and to detect the underlying condition at an
early gestation before PTL or PPROM occur. The results
of this study are important in the process of determin-
ing the etiology behind spontaneous PTD but due to
the non-significance after Bonferroni correction, the
results should be interpreted with caution. Previously
published research on the mid-trimester amniotic fluid
in relation to spontaneous PTD is inconclusive and
larger studies are required to examine whether one or
several candidate proteins can predict subsequent
spontaneous PTD in asymptomatic women in the
mid-trimester.
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